Insider Selling: Agios Pharmaceuticals, Inc. (AGIO) CEO Sells 80,000 Shares of Stock
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) CEO David P. Schenkein sold 80,000 shares of Agios Pharmaceuticals stock in a transaction that occurred on Wednesday, October 4th. The shares were sold at an average price of $70.14, for a total value of $5,611,200.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Agios Pharmaceuticals, Inc. (AGIO) traded up 0.81% on Thursday, hitting $70.82. 320,924 shares of the stock were exchanged. Agios Pharmaceuticals, Inc. has a 1-year low of $39.24 and a 1-year high of $71.40. The company’s market capitalization is $3.43 billion. The company has a 50-day moving average price of $63.02 and a 200 day moving average price of $55.90.
Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.78) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.57) by ($0.21). The firm had revenue of $11.30 million for the quarter, compared to analyst estimates of $10.68 million. Agios Pharmaceuticals had a negative return on equity of 68.15% and a negative net margin of 502.12%. The business’s revenue was up 62.1% on a year-over-year basis. During the same quarter in the prior year, the business posted ($1.47) EPS. Analysts anticipate that Agios Pharmaceuticals, Inc. will post ($7.08) EPS for the current fiscal year.
A number of research firms have weighed in on AGIO. SunTrust Banks, Inc. reaffirmed a “buy” rating and set a $80.00 price objective on shares of Agios Pharmaceuticals in a report on Wednesday. J P Morgan Chase & Co reaffirmed a “buy” rating and set a $76.00 price objective on shares of Agios Pharmaceuticals in a report on Monday, September 18th. Royal Bank Of Canada began coverage on Agios Pharmaceuticals in a report on Thursday, September 14th. They set an “outperform” rating and a $78.00 price objective on the stock. Canaccord Genuity set a $90.00 price objective on Agios Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, August 2nd. Finally, ValuEngine raised Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Three analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $75.20.
Several hedge funds and other institutional investors have recently bought and sold shares of AGIO. Bank of Montreal Can boosted its position in shares of Agios Pharmaceuticals by 11.7% during the 1st quarter. Bank of Montreal Can now owns 2,068 shares of the biopharmaceutical company’s stock worth $121,000 after acquiring an additional 216 shares in the last quarter. Blue Sky Asset Management LLC acquired a new stake in shares of Agios Pharmaceuticals during the 1st quarter worth approximately $129,000. QS Investors LLC acquired a new stake in shares of Agios Pharmaceuticals during the 2nd quarter worth approximately $144,000. Russell Investments Group Ltd. boosted its position in shares of Agios Pharmaceuticals by 163.9% during the 1st quarter. Russell Investments Group Ltd. now owns 2,549 shares of the biopharmaceutical company’s stock worth $149,000 after acquiring an additional 1,583 shares in the last quarter. Finally, Cubist Systematic Strategies LLC boosted its position in shares of Agios Pharmaceuticals by 1,041.0% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 3,423 shares of the biopharmaceutical company’s stock worth $176,000 after acquiring an additional 3,123 shares in the last quarter. Institutional investors and hedge funds own 94.40% of the company’s stock.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.